PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27572707-0	2016	A simple and efficient synthesis of novel inhibitors of alpha-glucosidase based on benzimidazole skeleton and molecular docking studies.	benzimidazole	83-96	sucrase-isomaltase	Homo sapiens	56-73	
26894559-1	2016	Benzimidazole analogs 1-27 were synthesized, characterized by EI-MS and (1)HNMR and their alpha-glucosidase inhibitory activities were found out experimentally.	benzimidazole	0-13	sucrase-isomaltase	Homo sapiens	90-107	
31838286-1	2020	In this study, a series of benzimidazole-1,2,3-triazole hybrids 8a-n as new alpha-glucosidase inhibitors were designed and synthesized.	benzimidazole	27-55	sucrase-isomaltase	Homo sapiens	76-93	
34153810-4	2021	The target benzimidazole 3f containing hydroxyl motif at para-position of phenyl revealed an important activity inhibitor against alpha- amylase (IC50 = 12.09 +- 0.38 microM) and alpha-glucosidase (IC50 = 11.02 +- 0.04 microM) comparable to the reference drug acarbose.	benzimidazole	11-24	sucrase-isomaltase	Homo sapiens	179-196	
31699396-0	2020	Synthesis, in vitro alpha-glucosidase inhibitory potential of benzimidazole bearing bis-Schiff bases and their molecular docking study.	benzimidazole	62-75	sucrase-isomaltase	Homo sapiens	20-37	
31699396-5	2020	Current study deals with the synthesis and biological screening of benzimidazole bearing bis-Schiff bases (1-19) for their alpha-glucosidase inhibitory activity.	benzimidazole	67-80	sucrase-isomaltase	Homo sapiens	123-140	
31838286-0	2020	Synthesis and biological evaluation of new benzimidazole-1,2,3-triazole hybrids as potential alpha-glucosidase inhibitors.	benzimidazole	43-71	sucrase-isomaltase	Homo sapiens	93-110	
30411010-0	2018	Efficient Synthesis and in Silico Studies of the Benzimidazole Hybrid Scaffold with the Quinolinyloxadiazole Skeleton with Potential alpha-Glucosidase Inhibitory, Anticoagulant, and Antiplatelet Activities for Type-II Diabetes Mellitus Management and Treating Thrombotic Disorders.	benzimidazole	49-62	sucrase-isomaltase	Homo sapiens	133-150	
30411010-4	2018	In addition, molecular docking studies revealed that benzimidazole-containing quinolinyl oxadiazoles can correctly dock into the target receptor protein of the human intestinal alpha-glucosidase, while their bioavailability/drug-likeness was predicted to be acceptable but requires further optimization.	benzimidazole	53-66	sucrase-isomaltase	Homo sapiens	177-194	
30411010-9	2018	These findings reveal that benzimidazole-containing quinolinyl oxadiazoles act as alpha-glucosidase inhibitors to develop novel therapeutics for treating type-II diabetes mellitus and can act as lead molecules in drug discovery as potential antidiabetic and antithrombotic agents.	benzimidazole	27-40	sucrase-isomaltase	Homo sapiens	82-99